Andrew J. Stewart - Apr 24, 2023 Form 4 Insider Report for Bausch & Lomb Corp (BLCO)

Signature
/s/ Debra E. Levin, attorney-in-fact
Stock symbol
BLCO
Transactions as of
Apr 24, 2023
Transactions value $
$0
Form type
4
Date filed
4/26/2023, 05:22 PM
Next filing
Mar 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLCO Common Shares, No Par Value Award $0 +33.2K $0.00 33.2K Apr 24, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the grant of restricted stock units ("RSUs") under the Amended and Restated Bausch + Lomb Corporation 2022 Omnibus Incentive Plan which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation.

Remarks:

The Reporting Person's title as an officer of the Issuer is President, Ophthalmic Pharmaceuticals.